GLP-1 Wegovy Zepbound Coverage Lost 2026: How Employers Made This Call and What You Can Demand From HR

# GLP-1 Wegovy Zepbound Coverage Lost 2026: How Employers Made This Call and What You Can Demand From HR

> **Quick answer:** In 2026, roughly 12 million people lost employer-sponsored coverage for Wegovy and another 12 million lost Zepbound, according to GoodRx research. Employers cut coverage because GLP-1 weight-loss drugs consumed up to 21% of pharmacy benefit budgets — but most employers dropped only the weight-loss indication, not diabetes use. That distinction creates five specific things you can negotiate with HR right now, from medical-necessity appeals to lifestyle-program carve-ins that restore access.

*This article is for informational purposes only and does not replace professional medical advice. Consult a qualified healthcare provider for decisions about your medications and treatment plan. It does not constitute financial or legal advice.*

GLP-1 Wegovy Zepbound coverage lost 2026 is the benefits headline hitting millions of workers who relied on employer health plans to make a $1,000-per-month drug affordable. But the story most outlets are telling — "here are your savings card options" — skips a chapter that actually matters: understanding exactly how your employer made this decision, and what that decision-making anatomy reveals about where you still have leverage.

The Peterson-KFF Health System Tracker published focus group research with HR leaders and benefits managers at large employers in 2025. It is the most detailed public record of how companies reasoned through the GLP-1 coverage question. What it reveals is that most employers did not make a clean, irreversible cut — they made a cost-management decision with several soft spots employees can press.

## How 12 Million People Lost Coverage: The Employer Math